A Potential Inhibitory Role for the New Truncated Variant of Somatostatin Receptor 5, sst5TMD4, in Pituitary Adenomas Poorly Responsive to Somatostatin Analogs | Zendy

Mario DuránPrado | Zendy; Alexandru Saveanu | Zendy; Raúl M. Luque | Zendy; Manuel D. Gahete | Zendy; Francisco GraciaNavarro | Zendy; P Jaquet | Zendy; Henry Dufour | Zendy; Marı́a M. Malagón | Zendy; Michael D. Culler | Zendy; Anne Barlier | Zendy; Justo P. Castaño | Zendy

Open Access

A Potential Inhibitory Role for the New Truncated Variant of Somatostatin Receptor 5, sst5TMD4, in Pituitary Adenomas Poorly Responsive to Somatostatin Analogs

Author(s) -

Mario DuránPrado,

Alexandru Saveanu,

Raúl M. Luque,

Manuel D. Gahete,

Francisco GraciaNavarro,

P Jaquet,

Henry Dufour,

Marı́a M. Malagón,

Michael D. Culler,

Anne Barlier,

Justo P. Castaño

Publication year - 2010

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2009-2247

Subject(s) - somatostatin , somatostatin receptor , in vivo , octreotide , somatostatin receptor 2 , medicine , endocrinology , agonist , receptor , in vitro , context (archaeology) , biology , hormone , pituitary tumors , biochemistry , paleontology , microbiology and biotechnology

Somatostatin (SST) receptors, specially sst2 and sst5, provide a valuable target to inhibit excessive hormone release and cell growth in pituitary tumors by using SST analogs (SSAs). Unfortunately, an appreciable proportion of tumors fail to respond to SSA despite expressing high levels of one or more ssts. Recently we identified two novel truncated sst5 variants, sst5TMD5, and sst5TMD4, absent in normal pituitary but expressed in pituitary tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research